XZ-700 is under clinical development by Micreos and currently in Phase II for Staphylococcus aureus Infections. According to GlobalData, Phase II drugs for Staphylococcus aureus Infections have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XZ-700’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

XZ-700 overview

XZ-700 is under development for the treatment of Staphylococcus aureus colonization in atopic dermatitis and cutaneous T-cell lymphoma. The drug candidate is a next-generation recombinant endolysin. It acts by targeting the cell membrane. It is developed based on endolysin technology. It is administered through topical route.

Micreos overview

Micreos develops targeted antibacterial products. The company utilizes endolysin technology to kill unwanted bacteria by preserving the beneficial bacteria. It applies endolysin technology in many areas including human health, food safety, animal health and agriculture. Micreos supplies human health products under the Gladskin brand and food safety products under the Phageguard brand. The Gladskin product provides treatment for staphylococcus aureus, colonization infection continuum, eczema, rosacea, acne, folliculitis and furunculosis. The company undertakes various research and development activities in the field of agriculture for crop protection. It has operations across the Netherlands. Micreos is headquartered in The Hague, Zuid-Holland, The Netherlands.

For a complete picture of XZ-700’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.